{"id":"leo-90100","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Application site pain"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting phosphodiesterase 4, LEO 90100 increases intracellular cAMP levels in immune and inflammatory cells, suppressing the release of pro-inflammatory mediators such as TNF-α and IL-23. This mechanism reduces skin inflammation and is designed for topical treatment of inflammatory skin conditions.","oneSentence":"LEO 90100 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:42.466Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atopic dermatitis"},{"name":"Psoriasis"}]},"trialDetails":[{"nctId":"NCT05919082","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2023-06-21","conditions":"Stable Plaque Psoriasis","enrollment":604},{"nctId":"NCT03806790","phase":"PHASE3","title":"Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2019-01-24","conditions":"Psoriasis Vulgaris","enrollment":182},{"nctId":"NCT01866163","phase":"PHASE3","title":"LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-06","conditions":"Psoriasis Vulgaris","enrollment":426},{"nctId":"NCT02132936","phase":"PHASE3","title":"LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-06","conditions":"Psoriasis Vulgaris","enrollment":504},{"nctId":"NCT02387853","phase":"PHASE2","title":"Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-03","conditions":"Psoriasis Vulgaris","enrollment":117},{"nctId":"NCT02310646","phase":"PHASE3","title":"Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01","conditions":"Psoriasis Vulgaris","enrollment":219},{"nctId":"NCT02518048","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-08","conditions":"Skin and Connective Tissue Diseases","enrollment":35},{"nctId":"NCT01600222","phase":"PHASE2","title":"Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":37},{"nctId":"NCT01536886","phase":"PHASE2","title":"LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":376},{"nctId":"NCT01536938","phase":"PHASE2","title":"LEO 90100 in the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":303},{"nctId":"NCT01347255","phase":"PHASE2","title":"A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-05","conditions":"Psoriasis Vulgaris","enrollment":24},{"nctId":"NCT01935869","phase":"PHASE1","title":"Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-08","conditions":"Psoriasis Vulgaris","enrollment":224},{"nctId":"NCT02416258","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Skin and Connective Tissue Diseases","enrollment":50},{"nctId":"NCT01946386","phase":"PHASE1","title":"A Vasoconstriction Study With LEO 90100","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09","conditions":"Psoriasis Vulgaris","enrollment":35},{"nctId":"NCT03442244","phase":"PHASE1","title":"Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-01-30","conditions":"Psoriasis Vulgaris","enrollment":20},{"nctId":"NCT03476746","phase":"PHASE1","title":"Dermatopharmacokinetic Trial of LEO 90100 Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-03-20","conditions":"Healthy","enrollment":58},{"nctId":"NCT02899962","phase":"PHASE3","title":"LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-02-15","conditions":"Psoriasis Vulgaris","enrollment":722},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["calcipotriol 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate)"],"phase":"phase_3","status":"active","brandName":"LEO 90100","genericName":"LEO 90100","companyName":"LEO Pharma","companyId":"leo-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LEO 90100 is a topical phosphodiesterase 4 (PD4) inhibitor that reduces inflammatory cytokine production in skin. Used for Atopic dermatitis, Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}